VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing Data demonstrate potential of multiple TRACER capsids to target CNS disorders, including certain diseases that may benefit

Reader Interactions

Leave A Reply